Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT-biopsy study of capecitabine with or without sorafenib in HER2-negative breast cancer
2012-002053-29Phase 2Completed
- Sponsor
- Karolinska Institutet and University Hospital
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Capecitabine plus sorafenib with Capecitabine alone (2 arms). Primary endpoints: Identification of predictive gene-expression signatures and Correlation of tyrosine kinase receptor expression with phosphorylation status. Started Jul 2012; status: completed.
02
Drugs
sorafenibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002053-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002053-29.